Discover
TNYA
Tenaya Therapeutics, Inc.
0.75
2 x 0.52
2 x 0.96
bid
ask
+
0.01
0.92%
2 @ 04:00 PM
0.75 +0.00 (0.00%)
| Ytd | 4.76% | |
| 1y | 21.68% |
0.72
day range
0.75
0.53
52 week range
2.35
| Open | 0.74 | Prev Close | 0.74 | Low | 0.72 | High | 0.75 | Mkt Cap | 161.86M |
| Vol | 1.24M | Avg Vol | 3.61M | EPS | -0.44 | P/E | N/A | Forward P/E | -1.28 |
| Beta | 2.35 | Short Ratio | 2.31 | Inst. Own | 73.76% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-13 | 50-d Avg | 0.77 | 200-d Avg | 0.98 | 1yr Est | 18.50 |
TNYA News
benzinga.com
Tenaya Therapeutics Appoints Eric Hyllengren CFO, Effective July 13
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to d
globenewswire.com
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise Exper
benzinga.com
Tenaya Therapeutics Reports New Interim Safety And Efficacy Data From MyPEAK-1 Phase 1b/2 Clinical T
All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCMBenefits
benzinga.com
Tenaya Therapeutics To Report New Interim Data From Cohort 1 And 2 Of Ongoing MyPEAK-1 Phase 1b/2 Tr
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to di